Velmanase alfa-tycv

(Lamzede)

Velmanase alfa-tycv

Drug updated on 11/27/2023

Dosage FormInjection (intravenous: 1 mg/kg (actual body weight))
Drug ClassRecombinant human lysosomal alpha-mannosidase
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients.